Ignite Creation Date:
2025-12-25 @ 2:42 AM
Ignite Modification Date:
2026-02-26 @ 7:42 AM
Study NCT ID:
NCT05073133
Status:
COMPLETED
Last Update Posted:
2024-10-09
First Post:
2021-09-20
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA)
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Muscular Atrophy, Spinal | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Zolgensma | View |
| None | OAV101 | View |
| None | AVXS 101 | View |
| None | gene therapy | View |
| None | Muscle atrophy | View |
| None | SBMA | View |
| None | spinal and bulbar muscular atrophy | View |
| None | spinal muscular atrophy | View |
| None | bulbar muscular atrophy | View |
| None | muscle function | View |
| None | myopathy | View |
| None | muscle wasting | View |
| None | atrophied muscle | View |
| None | loss of muscle strength | View |